Tag: Complement inhibitor

The landscape of myasthenia gravis (MG) treatment has evolved beyond traditional immunosuppressants to include advanced, targeted injectable therapies. These newer options, including both subcutaneous injections and intravenous infusions, target specific components of the immune system to manage symptoms more effectively and improve quality of life.

Overactive complement system activity is a primary driver of several rare autoimmune diseases. For individuals with these challenging conditions, understanding *why do you take Ultomiris* is crucial to managing symptoms, preventing organ damage, and improving quality of life. This long-acting medication specifically targets a key protein in this immune pathway to provide sustained disease control.

Unlike many brand-name medications, the active ingredient avacopan is its own generic name, sold exclusively under the brand name Tavneos since its FDA approval in 2021. It is used to treat severe, active ANCA-associated vasculitis, offering a targeted approach to reduce inflammation and potentially lower dependency on high-dose steroids.

Over the last few years, the treatment landscape for myasthenia gravis (MG) has been revolutionized with the arrival of new, targeted therapies, moving beyond broad immunosuppression. A major development includes the approval of several new medications that specifically target key immune pathways, providing more effective and precise treatment options for patients asking, 'What is the new medicine for myasthenia gravis?'.

In 2025, the U.S. Food and Drug Administration (FDA) approved a significant new infusion for generalized myasthenia gravis (gMG), prompting many to ask what is the new pill for myasthenia gravis. While no new oral pill has been recently approved, recent advancements have focused on more targeted therapies delivered via injection or infusion that offer new hope for managing symptoms.

Without treatment from complement inhibitors, the 10-year survival rate for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) is just 65% [1.3.3]. Eculizumab revolutionized treatment for this and other rare diseases. But **how does Eculizumab work** to achieve this?

In October 2023, the U.S. Food and Drug Administration (FDA) approved zilucoplan (brand name ZILBRYSQ®), which became the first self-administered, once-daily injection for myasthenia gravis (MG). This new treatment option offers a convenient and flexible alternative for eligible adults with generalized MG who are anti-acetylcholine receptor (AChR) antibody-positive.

In a pivotal Phase 3 clinical trial, 65.7% of patients receiving Tavneos achieved sustained remission at 52 weeks, demonstrating significant efficacy compared to the standard prednisone taper. The key question for many is **how effective is Tavneos** in managing severe ANCA-associated vasculitis.